Best AI Penny Stocks Under $10 to Buy Now — USA (2026 Research Guide)
Looking for AI-related stocks under $10 that could offer high upside — but want realistic, research-backed names (no hype)? Below I cover five small-cap AI or AI-adjacent stocks trading under $10 in 2026, explain why they matter, list near-term catalysts and the risks you must accept before buying.
Quick snapshot — Why consider AI penny stocks under $10?
AI adoption across industries (voice assistants, machine learning for drug discovery, defense analytics, and automation) creates many small companies with real products — some trade under $10 and can move fast if they win contracts or release breakthroughs. But remember: higher reward = higher risk.
How I picked these names
I filtered for companies that (a) have explicit AI products or use AI in core services, (b) trade under $10 during early-2026, and (c) have public financials or recent news indicating traction. For each ticker I cite a reliable source so you can verify live prices and filings yourself.
1) SoundHound AI (SOUN) — Voice & conversational AI (trading under $10)
Why watch it: SoundHound builds voice AI and in-vehicle conversational platforms that can monetize via partnerships with automakers and merchants. The company reported strong revenue growth and raised 2025 guidance, showing real commercial traction. Recent price levels in early 2026 were under $10. 0
Key catalysts: in-car partnerships, expanded merchant voice commerce, quarterly revenue beats and improved guidance. 1
Risks: past filing delays, accounting scrutiny and volatility after big swings; this remains a high-volatility trade. 2
2) Veritone, Inc. (VERI) — AI operating system and media analytics (microcap, under $10)
Why watch it: Veritone offers aiWARE and AI media tools used in media, legal and government — a niche with steady recurring revenue. In early 2026 analysts were projecting upside and the stock was trading well below double-digit levels, making it an accessible AI name for speculative investors. 3
Key catalysts: new contracts with media and public sector, margin improvement and analyst coverage upgrades. 4
Risks: small revenue base vs peers, and sensitivity to client budgets.
3) Lantern Pharma (LTRN) — AI in drug discovery (clinical-stage biotech under $10)
Why watch it: Lantern applies genomics + machine learning to accelerate oncology drug development. While it's a biotech (not pure-play software AI), its use of AI in drug candidate selection makes it a legitimate “AI-adjacent” penny stock — and it traded under $10 in early 2026. Recent filings and investor materials describe their AI-led platform and pipeline activity. 5
Key catalysts: positive trial readouts, partnerships, orphan designation or licensing deals. Biotech catalysts can cause big moves — up or down. 6
Risks: clinical trial failure, dilution from fundraising, and sector volatility.
4) BigBear.ai (BBAI) — Decision intelligence & analytics (AI software under $10)
Why watch it: BigBear.ai provides AI-driven analytics for defense, government and commercial clients. In late-2025/early-2026 shares have traded in single-digit ranges and the company remains a widely followed small-cap AI name. Recent quarterly results and analyst commentary show mixed signals but continued market interest. 7
Key catalysts: government contract clarity, revenue stabilization, and margin improvement. 8
Risks: accounting restatements, revenue downside from contract uncertainty — this stock is speculative. 9
5) Canaan Inc. (CAN) — AI chip / hardware exposure (chipmaker trading under $1 in 2026)
Why watch it: Canaan manufactures AI/crypto mining hardware. Market cycles in chips and demand for AI accelerators can swing its revenue and share price dramatically. As of early 2026 Canaan was trading well below $1, making it a true "penny" by price. 10
Key catalysts: uptick in demand for AI accelerators or favorable crypto cycles; supply contract wins. Risks: commodity-like business, cyclical demand and thin margins.
How to approach these AI penny stocks (practical plan)
- Small position sizing: limit any single name to 1–3% of your total portfolio when you’re testing penny stocks.
- Use checklists: revenue trend, cash runway, recent contracts, management credibility and insider ownership.
- Watch catalysts: earnings, filings, FDA/clinical updates (for biotech), or government contracts (for defense/analytics names).
- Set stop-losses: penny stocks can gap down fast — plan your exit before you enter.
Topical authority — Related articles you should write next (internal linking suggestions)
- AI Stocks Under $50: Mid-risk names to consider
- How conversational AI is monetized in cars (case study: SoundHound)
- Biotech + AI: Lantern Pharma explained (how ML helps drug discovery)
- Defense AI contractors vs commercial AI vendors: what’s different?
FAQ — Quick answers
Q: Are these picks recommendations to buy?
No — this is research and education. These are high-risk small caps that deserve careful due diligence. Always cross-check current prices and filings. (See sources below.)
Q: Can penny AI stocks make big gains?
Yes — but they can also lose most value. If a small company lands a major contract or successful trial, stock moves can be large; conversely, setbacks can wipe out equity.
Q: Where to check live prices and filings?
Use official investor relations pages, SEC filings (EDGAR), and high-quality finance sites like Yahoo Finance, Nasdaq, Robinhood or MarketWatch — links cited in this article point to them. 11
References & recent sources (2026)
- SoundHound AI investor release and revenue update. 12
- SoundHound price and coverage (Robinhood / Yahoo). 13
- Veritone investor quote and analyst coverage. 14
- Lantern Pharma investor overview (AI in drug discovery). 15
- BigBear.ai price and recent earnings/news (MarketWatch / Investopedia / Barron’s). 16
- Canaan recent price and profile pages. 17
Author
StockWealthPro Editorial Team
We publish research-driven guides for USA investors focusing on practical, risk-aware strategies. Each article links to public filings and reputable finance sources — verify live quotes before trading.
Disclaimer
This article is educational and not financial advice. Stocks discussed are high-risk and price data changes frequently. Always do your own research (DYOR) and consult a licensed financial professional before investing. Past performance is not indicative of future results.